The CopCov Study

25/11/2021

https://m.youtube.com/watch?v=6zv799Otw2c

Perkembangan Vaksinasi COVID-19 & Alternatif Pencegahannya Hari/Tanggal: Rabu, 24 November 2021Waktu: 13.00-14.30 WIB

19/11/2021

https://www.youtube.com/watch?v=gM5aG4QGUJw

17/11/2021

We are pleased to announce that RSUP Dr. Sardjito is the latest site to recruit into the world’s largest prophylaxis study (nearly 4000 recruits), which still aims to answer the important question- do Chloroquine and Hydroxychloroquine prevent COVID-19.

The results of this study can still be beneficial to those who are not vaccinated around the world, if immunity wanes and if new variants come into circulation with decreased vaccine efficacy.

For more information on this research, please contact [email protected]

Patient-centred research is the core of our research activities, spanning 5 research units and over 50 research sites in Asia and Africa.

20/09/2021

Today the COPCOV study has reached the important milestone of 3,000 participants enrolled!!! A fantastic contribution to recruitment from many sites and participants around the world (Benin, Côte d’Ivoire, Indonesia (Surabaya and Medan), Kenya (Mbagathi and Eldoret), Mali, Nepal, Niger, Pakistan, Thailand, the U.K. and Zambia).

07/09/2021

Congratulations to the fantastic team at the Fountain Health Care Hospital, Eldoret, Kenya!! The latest site to be recruiting into the COPCOV study. Next milestone- 3,000 participants.

01/09/2021

B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal has recruited more than 200 participants into the COPCOV study over the last month!! A great testament to the team’s hard work and perseverance in the face of sizeable challenges.

01/09/2021

The COPCOV study is open and recruiting in Niamey, Niger. The study is currently active in 12 other African sites in 6 countries and with >2,400 participants at last count, aims to help answer the question as to the role of HCQ in prevention of COVID-19.

06/08/2021

Bunda Tharmin Hospital & Teguh Memorial Hospital (Medan, Indonesia) have begun recruitment and the study total is now >1,700 participants. Amazing effort from all those involved but still much to be done!

06/08/2021

Why study chloroquine/hydroxychloroquine in COVID19 prevention?

For more information please contact:[email protected]" rel="ugc" target="_blank">https://www.tropmedres.ac/covid-19/[email protected] English subtitles.The trial is funded through ...